Showing results (181-190 of 219) with videos related to
Sort By:
Pageof 22
British Journal of Clinical Pharmacology|February 1, 1980
The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patientsG G Skellern, B I Knight, C K Low, et al.Lancet (London, England)|February 14, 2003
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialT S Maughan, R D James, D J Kerr, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trialG C Wishart, D Bissett, J Paul, et al.European Journal of Cancer & Clinical Oncology|September 1, 1987
The effect of the non-ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer, spheroid and clonogenic culture systemsD J Kerr, T E Wheldon, J G Russell, et al.Cancer Research|June 1, 1986
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester)D J Kerr, S B Kaye, J Graham, et al.Clinical Endocrinology|March 1, 1976
Total thyroidal content of iodine in thyrotoxic patients measured by in vivo neutron activation analysisI Robertson, K Boddy, M J Hooper, et al.The Journal of Clinical Endocrinology and Metabolism|May 1, 1975
Thyroid function in patients in clinical remission after medical treatment of thyrotoxicosisM J Hooper, J G Ratcliffe, W A Ratcliffe, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|March 10, 2001
Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumorsA H Djeha, T A Thomson, H Leung, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetinP J Mulholland, D R Ferry, D Anderson, et al.Hematological Oncology|January 1, 1990
The myelotoxicity of carboplatin is influenced by the time of its administrationD J Kerr, C Lewis, B O'Neil, et al.Pageof 22